OpenScience.ink

1 week ago • Frontiers in drug safety and regulation

Panic Attacks After Tirzepatide Injection in Two Women with Recurrent DepressionCase Report: Panic attacks after tirzepatide injection in two female patients with recurrent depressive disorder.

📖 Top 50% JournalCase Reports

1 week ago • Diabetes, obesity & metabolism

How Accurately Is Nausea Measured in Obesity Trials Using GLP-1 Treatments?How Well Are We Measuring Nausea? A Narrative Review of Patient-Reported Outcome Gaps in GLP-1 Receptor Agonist Obesity Trials.

Article

1 week ago • Obesity pillars

One-year weight loss patterns and factors linked to response with personalized tirzepatide dosing in real-world settings12-month weight-loss trajectories and predictors of response to tirzepatide under individualized dosing: A multicenter real-world study.

📖 Top 20% JournalArticle

1 week ago • JAMA

Patterns of Dispensing Combined GLP-1 Treatments with Vitamin B12Compounded GLP-1 Dispensing Patterns and Vitamin B12 Coformulation.

Article

1 week ago • Journal of medicinal chemistry

Oral Small-Molecule Drugs That Activate GLP-1 Receptors: Insights from Clinical Trials and Guidelines for Future DevelopmentOral Small-Molecule GLP-1 Receptor Agonists: Lessons from Clinical Candidates and a Blueprint for Next-Generation Design.

🎖️ Top 10% JournalArticle

1 week ago • Journal of laparoendoscopic & advanced surgical techniques. Part A

Factors linked to not moving forward with weight-loss surgery in very severely obese patients at a community centerClosing the Gap to Bariatric Surgery: Predictors of Non-Progression in Patients with Obesity Class IV and V at a Community-Based Bariatric Center.

📖 Top 50% JournalArticle

1 week ago • Annals of hepatology

Current treatments and challenges for fatty liver disease linked to metabolismPharmacotherapy for MASLD: current evidence and challenges in clinical practice.

📖 Top 20% JournalArticle

1 week ago • European journal of pediatrics

Treating childhood fatty liver disease by targeting the gut-liver connection and gut bacteria: current knowledge and future optionsTargeting the gut-liver axis and gut microbiome in pediatric metabolic dysfunction-associated steatotic liver disease: current evidence and future directions.

📖 Top 20% JournalArticle

1 week ago • Annual review of physiology

New Developments in Treatments Using Incretin HormonesNew Horizons for Incretin-Based Therapeutics.

🥇 Top 1% JournalArticle

1 week ago • Cureus

Onset and Progression of Diabetic Eye Disease During Treatment with Semaglutide or Tirzepatide, Including a Review of a Specific Type of Optic Nerve DamageDiabetic Retinal Disease Onset and Progression During Established Semaglutide or Tirzepatide Treatment: A Retrospective Comparative Cohort Study With a Descriptive Regional Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) Review.

Article

1 week ago • Hormone research in paediatrics

Semaglutide treatment in two very young children with severe early obesitySEMAGLUTIDE TREATMENT IN TWO VERY YOUNG CHILDREN WITH SEVERE EARLY-ONSET OBESITY.

📖 Top 20% JournalCase Reports

1 week ago • European journal of clinical pharmacology

GLP-1 Treatments for Heart Disease: Results, How They Work, and New Medical UsesGLP-1-based therapies in cardiovascular disease: outcomes, mechanisms, and emerging clinical applications.

📖 Top 20% JournalArticle

1 week ago • Journal of medical Internet research

Widespread GLP-1 Antibodies and Their Impact on Body Weight RegulationGLP-1 Ads Are Everywhere. What Are They Doing to Our Body Image?

🥉 Top 5% JournalArticle

1 week ago • Neuroendocrinology

Butyrate may boost Semaglutide’s effect on reducing obesityButyrate enhances the obesity reduction effect of Semaglutide.

📖 Top 20% JournalArticle

1 week ago • Diabetes, obesity & metabolism

Long-Term Compared to Short-Term GLP-1 Receptor Agonist Use and Metabolic Health in Older Adults Without DiabetesSustained Versus Minimal GLP-1 Receptor Agonist Exposure and Metabolic Outcomes in Older Adults Without Diabetes.

Article

1 week ago • GeroScience

What dog lifespan treatments can teach us about human healthLessons from dog lifespan therapeutics for their human companions.

🎖️ Top 10% JournalArticle

1 week ago • ACS nano

Using mRNA Nanoparticles Delivered to the Gut for Whole-Body Vaccines and Metabolic TreatmentTargeted Gastrointestinal Delivery of mRNA Lipid Nanoparticles Enables Systemic Vaccination and Glucagon-like Peptide-1 Metabolic Therapy.

🥈 Top 2% JournalArticle

1 week ago • Endocrinology and metabolism (Seoul, Korea)

Temporary Fat Tissue Inflammation Changes During Rapid Weight Loss and Regain Caused by High-Dose SemaglutideTransient Adipose Inflammatory Remodeling during High-Dose Semaglutide-Induced Weight Loss and Regain.

🎖️ Top 10% JournalArticle

1 week ago • Central European journal of urology

What Urologists Should Know About Weight Loss and Kidney Stones with Glucagon-Like Peptide-1 Receptor AgonistsGlucagon-like peptide-1 receptor agonists, weight loss, and urolithiasis: what urologists should know.

📖 Top 50% JournalArticle

1 week ago • The Journal of the Association of Physicians of India

Practical Challenges and Factors Linked to Success in GLP-1 Receptor Agonist TreatmentReal-world Challenges and Predictors of Success in Glucagon-like Peptide-1 Receptor Agonist Therapy.

Article

1 week ago • The Journal of the Association of Physicians of India

Healthcare Professionals' Views on Newer Weight Loss Drugs Semaglutide and Tirzepatide in South AsiaPerspectives on Newer Antiobesity Drugs (Semaglutide and Tirzepatide) among Healthcare Professionals Treating Obesity in South Asia: A Cross-sectional Survey.

Article

1 week ago • Diabetology & metabolic syndrome

Ecnoglutide's safety and treatment effects for type 2 diabetes: a review and combined analysisEvaluating the therapeutic benefits and safety of ecnoglutide for type 2 diabetes: evidence from a systematic review and meta-analysis.

📖 Top 20% JournalArticle

1 week ago • European journal of orthopaedic surgery & traumatology : orthopedie traumatologie

Comparing drugs that target both GIP and GLP-1 receptors versus only GLP-1 receptor in patients having knee or hip replacement surgeryDual GIP/GLP-1 receptor agonist versus selective GLP-1 receptor agonist in patients undergoing primary total knee or hip arthroplasty.

📖 Top 30% JournalComparative Study

1 week ago • Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery

Comparing weight-loss surgery and diabetes drugs in dialysis patients with obesity and diabetesMetabolic bariatric surgery versus GLP-1 receptor agonists in dialysis patients with diabetes and obesity: a target trial emulation study.

📖 Top 20% JournalArticle

1 week ago • Frontiers in endocrinology

Molecular signals linking tissue problems to whole-body insulin resistanceMolecular signaling networks that connect tissue dysfunction to systemic insulin resistance.

🎖️ Top 10% JournalArticle

1 week ago • Obesity reviews : an official journal of the International Association for the Study of Obesity

Cancer Risk Linked to Using GLP-1 Medicines for Treating ObesityGLP-1 Receptor Agonists and Cancer Risk in Obesity Treatment.

Article

1 week ago • EClinicalMedicine

Weight loss and blood pressure changes with GLP-1 and multi-hormone drugs in overweight and obese adultsWeight loss and blood pressure lowering with GLP-1 receptor agonists and multi-hormone receptor modulators in overweight and obesity: a systematic review and meta-regression of phase 3 clinical trials.

🥈 Top 2% JournalArticle

1 week ago • Current obesity reports

Understanding the Safety of GLP-1 Receptor Agonists: Facts, Myths, and Current DebatesDecoding the Safety Profile of GLP-1 Receptor Agonists: Facts, Myths, and Ongoing Controversies.

🥉 Top 5% JournalArticle

1 week ago • EClinicalMedicine

Cardiorenal trials should report absolute risk reduction and number needed to treat, not just relative risk reductionRelative risk reduction is not enough: why cardiorenal trials should routinely report absolute risk reduction and number needed to treat.

🥈 Top 2% JournalArticle

1 week ago • Psychological medicine

Semaglutide may influence decision-making between exploring and exploiting options in major depressionSemaglutide modulates explore/exploit decision-making in major depressive disorder: A randomized clinical trial.

Randomized Controlled Trial

← prevpage 7 of 16next →

Latest GLP-1 Therapies Research Papers